Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)
Open Access
- 9 October 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 178 (3), 674-681
- https://doi.org/10.1111/bjd.16050
Abstract
Background Ixekizumab, a high‐affinity monoclonal antibody that selectively targets interleukin (IL)‐17A, is approved for the treatment of moderate‐to‐severe psoriasis. Objectives This analysis represents an overview of the efficacy outcomes from three phase III psoriasis studies. Methods Data were integrated from the 12‐week induction period of three studies in which patients received ixekizumab 80 mg every 2 weeks (IXE Q2W; n = 1169) or every 4 weeks (IXE Q4W; n = 1165) after an initial 160‐mg dose for both; etanercept (50 mg biweekly; n = 740; two studies) or placebo (n = 792). The coprimary end points were the percentages of patients with response of static Physician's Global Assessment (sPGA; score 0 or 1) and ≥ 75% improvement in baseline Psoriasis Area and Severity Index (PASI 75) at week 12. Response rates were compared between treatments using the Cochran–Mantel–Haenszel test stratified by study. Treatment comparisons with placebo included data from three studies, whereas etanercept comparisons were based on two studies. Results Ixekizumab treatment was superior to placebo (P < 0·001) and etanercept (P < 0·001) on sPGA (0, 1) and PASI 75, with significant differences in PASI improvement at week 1. With IXE Q2W, at week 12, the frequencies of patients achieving PASI 75, 90 and 100 were nearly 90%, 70% and 40%, respectively. Ixekizumab‐treated patients showed significantly greater improvement vs. placebo and etanercept in percentage body surface area involvement and fingernail psoriasis. IXE Q2W was superior to IXE Q4W on all treatment outcomes. Conclusions Ixekizumab therapy at both dosing regimens demonstrated rapid onset and superior efficacy to placebo and etanercept, with IXE Q2W providing better outcomes than IXE Q4W during the first 12 weeks of treatment.Keywords
Funding Information
- Eli Lilly and Company
This publication has 22 references indexed in Scilit:
- Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modelingPatient Preference and Adherence, 2013
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and PrevalenceJournal of Investigative Dermatology, 2013
- Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunityNature Genetics, 2012
- Targeting IL-17 and TH17 cells in chronic inflammationNature Reviews Drug Discovery, 2012
- Living with Psoriasis: Prevalence of Shame, Anger, Worry, and Problems in Daily Activities and Social LifeActa Dermato Venereologica, 2012
- A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1Nature Genetics, 2010
- Geoepidemiology and environmental factors of psoriasis and psoriatic arthritisJournal of Autoimmunity, 2009
- PsoriasisNew England Journal of Medicine, 2009
- Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical TrialsDrug Information Journal, 2008
- Biologics for psoriasisNature Reviews Drug Discovery, 2003